PROteolysis Targeting Chimeras: A new cutting-edge nanomedicine for colorectal cancer

Clinical and translational discovery Pub Date : 2024-07-04 DOI:10.1002/ctd2.337

Swastika Maitra, Nobendu Mukerjee, Dattatreya Mukherjee, Arabinda Ghosh, Athanasios T. Alexiou

{"title":"PROteolysis Targeting Chimeras: A new cutting-edge nanomedicine for colorectal cancer","authors":"Swastika Maitra, Nobendu Mukerjee, Dattatreya Mukherjee, Arabinda Ghosh, Athanasios T. Alexiou","doi":"10.1002/ctd2.337","DOIUrl":null,"url":null,"abstract":"<p>Colorectal cancer (CRC) is a prevalent malignancy with a high mortality rate, necessitating innovative treatment strategies. PROTACs (PROteolysis Targeting Chimeras) represent a promising therapeutic approach by targeting and degrading oncogenic proteins via the ubiquitin-proteasome pathway. This study explores the potential of using exosomes as delivery vehicles for PROTACs to enhance treatment efficacy. Exosomes, due to their biocompatibility and inherent targeting capabilities, offer a precise method for delivering PROTACs to CRC cells, potentially overcoming challenges associated with traditional therapies such as drug resistance and off-target effects. By harnessing the advantages of both exosome-based delivery and PROTAC technology, this approach aims to improve targeted protein degradation and therapeutic outcomes in CRC treatment. Further research is required to optimize exosome engineering, ensure efficient PROTAC loading, and validate the safety and efficacy of this novel therapeutic strategy through preclinical and clinical trials.</p>","PeriodicalId":72605,"journal":{"name":"Clinical and translational discovery","volume":"4 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctd2.337","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and translational discovery","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/ctd2.337","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Colorectal cancer (CRC) is a prevalent malignancy with a high mortality rate, necessitating innovative treatment strategies. PROTACs (PROteolysis Targeting Chimeras) represent a promising therapeutic approach by targeting and degrading oncogenic proteins via the ubiquitin-proteasome pathway. This study explores the potential of using exosomes as delivery vehicles for PROTACs to enhance treatment efficacy. Exosomes, due to their biocompatibility and inherent targeting capabilities, offer a precise method for delivering PROTACs to CRC cells, potentially overcoming challenges associated with traditional therapies such as drug resistance and off-target effects. By harnessing the advantages of both exosome-based delivery and PROTAC technology, this approach aims to improve targeted protein degradation and therapeutic outcomes in CRC treatment. Further research is required to optimize exosome engineering, ensure efficient PROTAC loading, and validate the safety and efficacy of this novel therapeutic strategy through preclinical and clinical trials.

Abstract Image

查看原文本刊更多论文

PROteolysis 靶向嵌合体：治疗结直肠癌的新型尖端纳米药物

结直肠癌（CRC）是一种死亡率很高的常见恶性肿瘤，因此需要创新的治疗策略。PROTACs（PROteolysis Targeting Chimeras）通过泛素-蛋白酶体途径靶向和降解致癌蛋白，是一种很有前景的治疗方法。本研究探讨了利用外泌体作为 PROTACs 的递送载体来提高疗效的可能性。外泌体具有生物相容性和固有的靶向能力，为向 CRC 细胞递送 PROTACs 提供了一种精确的方法，有可能克服与传统疗法相关的挑战，如耐药性和脱靶效应。通过利用基于外泌体的递送和 PROTAC 技术的优势，这种方法旨在改善 CRC 治疗中的靶向蛋白降解和治疗效果。还需要进一步的研究来优化外泌体工程，确保高效的 PROTAC 负载，并通过临床前和临床试验验证这种新型治疗策略的安全性和有效性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and translational discovery

CiteScore

1.00

自引率

0.00%

发文量